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ABSTRACT 
 
Crystal Structures of Binary and Ternary Complexes of 
Thymidylate Synthase (ThyA) from Mycobacterium 
tuberculosis: Insights into Selectivity and Inhibition. 
(August 2011) 
Wayne Daniel Harshbarger, B.S., Virginia Commonwealth University 
Chair of Advisory Committee: Dr. James Sacchettini 
 
 Thymidylate synthase (TS), encoded by the ThyA gene, is essential for 
the growth and survival of Mycobacterium tuberculosis and therefore is a 
potential drug target. Thymidylate synthase binds both a substrate, 2’-
deoxyuridine-5’monophosphate (dUMP) as well as a cofactor, (6R,S)-5,10-
methylenetetrahydrofolate (mTHF), providing the ability to inhibit a single target 
by two  separate classes of molecules.  5’-fluoro-2’-deoxyuridine-5’-
monophosphate (FdUMP) is a very tight binding mechanism based inhibitor, 
shown to have a Ki of 2nM for Mtb TS. Pemetrexed and Raltitrexed are both 
anti-folates, targeting the cofactor binding site of thymidylate synthase.  
The x-ray crystal structures of Mycobacterium tuberculosis thymidylate 
synthase were solved in the binary complexes ThyA-dUMP and ThyA-FdUMP at 
2.5 Å and 2.4 Å resolutions, respectively. The ternary complex, ThyA-dUMP-
Pemetrexed was solved to a resolution of 1.7 Å. The enzyme is comprised of 8 
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-helices as well as 23% of the protein formed by -sheets, including the dimer 
interface which is a -sandwich. Examination of the dUMP binding site allowed 
the identification of key conserved residues that play a role in ligand binding and 
catalysis. Comparison of the dUMP-Pemetrexed ternary complex with that of the 
human crystal structure shows two fewer interactions in the Mtb enzyme. One is 
due to the replacement of a Met with a Val which doesn’t allow hydrophobic 
interactions with the ring system of Pemetrexed, and the other is the 
replacement of an Asn with a Trp, depriving the Mtb protein of a hydrogen bond 
at the N7 of the pyrrolo ring. 
 A spectrophotometric assay that monitored DHF formation was used to 
determine the inhibition of Pemetrexed and Raltitrexed on Mtb TS. Both were 
verified as noncompetitive inhibitors, and Pemetrexed was found to have an IC50 
of 17M and a Ki of 16.8M, while Raltitrexed had an IC50 of 3.5M and a Ki of 
3.2M.  
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1. INTRODUCTION: Mycobacterium tuberculosis 
1.1 Global Tuberculosis                                                                                
1.1.1 Tuberculosis Statistics       
 As of 1993, Mycobacterium tuberculosis, the bacteria responsible for 
tuberculosis, is a global health emergency, affecting one-third of the world’s 
population. Tuberculosis ranks 2nd only to HIV among infectious killers 
worldwide(1). M. tuberculosis typically infects the lungs, but can infect any part 
of the body, and when left untreated kills 50% of its victims. Of the 2 billion 
people infected with latent TB, over 9 million become sick with the active form of 
the bacteria, which can be spread to infect others(2). The mortality due to 
infection is greater than 2 million annually, as reported by the World Health 
Organization. There are an increasing number of Mycobacterium tuberculosis 
strains that are becoming resistant to antibiotics due to patients stopping their 
medication too soon, incorrect prescriptions, and poor quality of drugs. These 
strains are referred to as multidrug-resistant tuberculosis (MDR TB) and in some 
cases extensively drug resistant (XDR TB), and emphasize the need to pursue 
discovery of novel therapeutics to combat this disease(3, 4). Evidence of 
tubercular decay has been found in the skulls and spines of Egyptian mummies, 
indicating that TB has been infecting humans for at least 4,000 years. 
 
 
____________ 
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1.1.2 Risk Factors  
 Tuberculosis can affect anyone, but there are specific factors that can 
increase your body’s ability to become susceptible to the bacteria. A weakened 
immune system is a primary risk, and can be due to HIV infection, diabetes, 
chemotherapy for cancer, malnutrition, or age (Mayo Clinic).  Tuberculosis is 
found most abundantly in South Africa, with 940 cases reported per 100,000 
people, however huge areas of the world, including the Indian Subcontinent, Far 
East, China and the former Soviet Union, have rates between 100 and 300 per 
100,000 people (Figure 1)(5).   
 
        
 
 
1.1.3 Symptoms, Diagnosis and Cost of Treatment  
 Infection by Mycobacterium tuberculosis can lead to symptoms such as 
being easily tired, high fever, sharp chest pain accompanied by a cough, spitting 
up blood, and night sweats. Tuberculosis most commonly infects the lungs, but 
Figure 1- Global incidence and mortality of tuberculosis. 
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in 15% of patients it can be found to infect the lymph nodes, GI tract, or even 
bones and joints(6).  
 The Mantoux skin test can be used for identifying persons who are 
infected with TB. Approximately 0.1mL of purified protein derivative is injected 
under the skin which causes a delayed cellular hypersensitivity in persons 
infected. This is caused by re-stimulation of T-lymphocytes which have entered 
the bloodstream after being initially proliferated in response to infection. The 
result of a positive skin test is the appearance of a clearly defined, hard raised 
area at the point of injection (7-9). 
Chest X-rays are often used as a diagnostic tool to rule out TB in patients 
who have tested positive to the skin test. Tuberculosis of the lungs is 
distinguishable by infiltrates or cavities, and often many small nodules 
throughout the lungs(6).  
The only definitive way of determining infection is by a microbiological 
examination.  A specimen from a patient believed to be infected is examined 
either by DNA amplification by polymerase chain reaction, smear exams, or a 
BACTEC culture for tuberculosis.  A BACTEC culture uses enriched 
Middlebrook 7H12 14C labeled palmitic acid, in which mycobacterial growth can 
be detected by the utilization of 14C and release of 14CO2(10).  
 The world market for Tuberculosis drugs in 2006 was $370 million. In 
poor nations, a six month course of treatment can cost less than $20; however, 
in the US a two week treatment can cost as much as $200 (TBalliance.org). 
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1.1.4 Tuberculosis Drugs         
There are four main first line TB drugs, which when taken in combination 
can kill Mtb in 6-18 months, depending on the prescription given. The first of 
these drugs, Isoniazid, is a pro-drug that is activated by the KatG enzyme of 
Mycobacterium tuberculosis to form an isonicotinoyl radical(11). This radical 
then reacts non-enzymatically with oxidized NAD+ generating several 4-
isonicotinoyl-NAD adducts, one of which then targets the NADH dependent 
enoyl-acyl carrier protein reductase, InhA, while a second adduct has been 
shown to inhibit DHFR (Figure 2)(12, 13). Binding to InhA inhibits the action of 
fatty acid synthase, ultimately stopping the production of mycolic acid which is 
used to make the bacterial cell wall. Resistance to Isoniazid has been shown to 
be caused by a mutation of Ser94, which disrupts the H-bonding network 
stabilizing NADH to InhA (14). 
 
 
Figure 2- Isonicotinoyl-NAD adducts. Formed by Isoniazid after activation by 
KatG and non-enymatic oxidation by NAD
+
. The 4S isomer has been shown to 
inhibit InhA, while the 4R isomer targets DHFR. 
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Pyrazinamide,also a pro-drug, is activated to its lethal form, pyrazinoic 
acid, by the enzyme pyrazinamidase. The mode of action is largely unclear, but 
it has been shown in vitro to inhibit the activity of (FAS)1, which is required for 
the synthesis of fatty acids(15). Resistance to pyrazinamide develops through 
mutations in pncA, the gene encoding pyrazinamidase(16).  Pyrazinamide taken 
in combination with Isoniazide shortens the treatment time from 12-18 months, 
down to only six months. It does so by apparently killing a population of dormant 
bacteria that are not affected by the other first line drugs.  
Ethambutol is a simple diamine molecule which limits bacterial growth 
without killing the bacteria. It works in synergy with other first line TB drugs and 
targets arabinosyl transferases, EmbA and MbbB, which are responsible for 
arabinogalactan biosynthesis, another component of the bacterial cell wall(17). 
The mycobacterial cell wall core consists of two layers; the outer layer is made 
of mycolic acids, while the inner layer consists of peptidoglycan. These two 
layers are held together by arabinogalactan (Figure3).  
Rifampin is the most recently discovered first line antitubercular drug. It 
was discovered in 1966 and is a derivative of rifamycin B, an antibiotic produced 
by Streptomyces mediterranei (Figure 3)(18).  Rifampin inhibits DNA-dependent 
RNA polymerase, leading to suppression of RNA synthesis(19).  Mutations in 
the rpoB gene have been linked to rifampin resistance (20).  
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1.2 Thymidylate Synthase as a Drug Target  
1.2.1 De Novo Pathway and Essentiality of ThyA 
 Thymidylate synthase, ThyA, is an essential enzyme in most organisms, 
catalyzing the final step in the de novo pathway for synthesis of thymidine-5’-
monophosphate (dTMP). dTMP is a nucleotide required for DNA synthesis, and 
as such is an important potential drug target. In bacteria, deoxy-Uracil-
5’triphosphate (dUTP) is formed first; either by the phosphorylation of deoxy-
uracil-5’diphosphate (dUDP), or by the deamination of deoxycytidine 
triphosphate (dCTP) (Figure 5). dUTP is then converted to deoxyuracil 
monophosphate (dUMP) via dUTPase, and subsequently dTMP is formed by the 
action of Thymidylate synthase.  
Thymidylate synthase catalyzes the conversion of 2’-deoxyuridine-
5’monophosphate (dUMP) to thymidine-5’-monophosphate (dTMP) utilizing 
methylene-tetrahydrofolate (mTHF) as a methyl donor and reductant (Figure 4). 
Dihydrofolate (DHF) is a byproduct of this reaction, and goes on to be converted 
Figure 3- (Left) Rifampin, a first line TB antibiotic. (Right) A schematic of the bacterial cell wall. 
Mycolic acid synthesis is inhibited by Isoniazid, and arabinogalactan synthesis is inhibited by 
Ethambutol.  
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to tetrahydrofolate by the enzyme Dihydrofolate reductase, and is ultimately 
converted back to mTHF by serine hydroxymythl-transferase. Even partial 
inhibition of ThyA’s activity can lead to a buildup of 2’-deoxyuridine-5’-
triphosphate, which in turns leads to a “thymine-less” cell death(21, 22).   
 
 
 
 
 
 
Figure 5- De novo TMP synthesis. The de novo pathway for TMP synthesis beginning with 
cytidine diphosphate. The pathway can also begin with uracil diphosphate being reduced and 
subsequently phosphorylated, at which point the two pathways converge 
Figure 4- Thymidylate synthase reaction. ThyA catalyzes the conversion of 2’-deoxyuridine-
5’monophosphate to thymidine-5’-monophosphate utilizing methylene-tetrahydrofolate as the 
methyl donor and reductant. DHF is a byproduct. 
mTHF dUMP DHF dTMP 
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1.2.2 Mechanism of Thymidylate Synthase 
  The mechanism of Thymidylate synthase has been widely studied and is 
believed to be conserved across species. It has been validated by structures of 
reaction intermediate analogs with mechanism based inhibitors, and by site-
directed mutagenesis (Figure 7) (13, 23-25). During the reaction, mTHF serves 
as both the one-carbon donor to the substrate, dUMP, as well as the reductant. 
The carbon and the hydride come from different sites on the cofactor. The 
reaction mechanism proceeds via an ordered Bi-Bi fashion, with dUMP binding 
to thymidylate synthase first (Figure 6).  
 
 
 
 
Under conditions of saturating concentrations of mTHF, Kcat/Km
dUMP is 
equal to the on-rate for dUMP (25). The binding of cofactor is more complicated, 
due to the fact that it involves association with the binary complex, ThyA-dUMP, 
closing of the active site, opening of the imidazolidine ring, and covalent bond 
formation with C5 of dUMP.  
Figure 6- Bi-Bi Sequential Mechanism  
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 Catalysis begins by the nucleophilic attack of the active site Cysteine on 
C6 of dUMP, initiated by tight binding of the cofactor. Next is a 1,4-addition 
between the iminium ion (formed by opening of the mTHF ring) and C5 of 
dUMP, followed by abstraction of a proton from the C5 position of dUMP. -
elimination of the cofactor occurs next, and lastly the hydride transfer from 
mTHF to the methylene group at C5 of the pyrimidine.  The reaction mechanism 
is depicted in Figure 7.  The catalytic residues from L. casei were identified by 
site-directed mutagenesis, and of 25 conserved residues, five proved to be 
important for catalysis. In L. casei, these residues are Arg218 for dUMP binding, 
Asp221 for mTHF binding, Cys198 as the nucleophile attacking C6 of the 
pyrimidine, Tyr 146 for proton abstraction at the C5 position of dUMP, and Glu60 
is involved in cofactor elimination from the covalent ternary complex(26).   
 
 
 
 
Figure 7- Reaction mechanism of thymidylate synthase. Validated by structures of reaction 
intermediate analogs with mechanism based inhibitors, and by site-directed mutagenesis. 
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1.2.3 Chemotherapeutics that target Thymidylate Synthase   
 1.2.3.1 Substrate analog FdUMP 
 5’-fluoro-2’-deoxyuridine-5’-monophosphate (FdUMP), the active 
metabolite of 5-fluorouracil (5-FU), competes with the natural substrate of 
thymidylate synthase, dUMP, to form a ternary complex with the enzyme (Figure 
8). This complex does not dissociate easily and is deemed a dead-end inhibitor, 
since the fluoro group is located at the 5’ position, where typically a hydrogen 
atom would be abstracted (21, 22, 27). 
5-FU is commonly used to treat metastatic colorectal cancer, where the 
lack of dTMP, and buildup of dUMP, ultimately leads to the incorporation of 
deoxyuracil triphosphate into DNA. Other mechanisms of cytotoxicity include 
incorporation of FdUTP into DNA or FUTP into RNA. FdUTP incorporated into 
DNA during DNA synthesis leads to miscoding and eventually cell death (21).   
 
 
 
 
Figure 8- “Dead-end” inhibition of thymidylate synthase by FdUMP. 
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1.2.3.2 Pemetrexed   
 Pemetrexed is a pyrrolo[2,3-d]pyrimidine-based antifolate, which enters 
the cell and becomes polyglutamated by folypolyglutamate synthase (FPGS) 
(28).  The main target is inhibition of thymidylate synthase, where it acts as an 
anti-folate, binding in the mTHF site of the enzyme. Inhibition of dydrofolate 
reductase and glycinamide ribonucleotide formyl transferase is also seen(29). In 
combination with 5-FU, Pemetrexed has a synergistic antitumor effect on tumor 
types including non-small cell lung, breast, colorectal, head and neck, gastric, 
bladder, cervix, and pancreas cancers(30-32). In human cancer cells, the Ki for 
monglutamated Pemetrexed is reported to be 100-fold weaker than the 
polyglutamated form, with Ki’s of 109nM and 1.3nM, respectively.   
 1.2.3.3 Raltitrexed  
 Raltitrexed is another anti-folate that is rapidly taken up by the cell and is 
polyglutamated by FPGS. This polyglutamation leads to a 70-fold greater 
inhibition of thymidylate synthase, and has demonstrated activity in a variety of 
advanced solid tumors, such as colorectal and breast cancer (33-36). 
Furthermore, polyglutamation leads to a longer retention time in tumor cells, 
which reduces dosage, an option not possible with 5-FU.  Raltitrexed is a ThyA 
specific inhibitor, unlike 5-FU which inhibits purine synthesis and has effects not 
only on DNA but RNA as well. This makes Raltitrexed less toxic, not leading to 
side-effects such as mucositis (37).  
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Figure 9- Downstream effect of inhibiting thymidylate synthase. Disruption of the 
folate cycle, as well as reduction in cellular TMP, ultimately leads to cell death. 
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 2. STEADY STATE KINETICS AND INHIBITION OF Mtb ThyA 
2.1 Introduction 
 Thymidylate synthase (TS) plays a crucial role in DNA biosynthesis and 
cell proliferation, and has therefore been the focus of extensive research as a 
drug target against cancer as well as infectious agents such as M. tuberculosis. 
In order to characterize its activity, several in vitro assays have been developed 
to determine the potential therapeutic effectiveness of anti-folates. The use of 
folate based inhibitors is believed to be less toxic than drugs that mimic dUMP, 
such as FdUMP, which may be inadvertently integrated into DNA or RNA(21).  
   Antifolate inhibitors are of special interest for another reason as well; it is 
often found that several enzymes may be the target of a single drug, which is the 
case with Pemetrexed where it has been shown to inhibit both TS as well as 
Dihydrofolate Reductace (DHFR)(28, 29). Thymidylate synthase inhibitors are 
generally characterized by the presence of a 2-substituted-4-oxo moiety in the 
pyrimidine, as seen in both Pemetrexed and Raltitrexed, whereas DHFR anti-
folates will possess a 2,4-diamino in that position.  
 Due to the high degree of similarity between M. tuberculosis ThyA and 
other species, particularly in binding regions, the use of classical antifolates to 
combat tuberculosis may not prove to show enough discrimination between 
enzymes. For this reason, high throughput screening techniques to identify 
compounds that bind specifically to Mtb ThyA are an important tool for 
investigating species specificity.  One such assay, fluorescence-based thermal 
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shift, utilizes the energetic coupling between ligand binding and protein unfolding 
to identify fragments that may have an affinity for the protein. The temperature at 
which a purified protein unfolds is measured by an increase in fluorescence of a 
dye, Sypro orange. As the protein unfolds, Sypro orange binds to the 
hydrophobic patches that become exposed, causing an increase in fluorescence 
(38-41). This allows the ability to assay a diverse set up compounds and 
potentially identify non-classical TS inhibitor candidates.  
2.2 Experimental Procedures 
 Chemicals - 2′-Deoxyuridine 5′-monophosphate disodium salt, 5-Fluoro-
2′-deoxyuridine 5′-monophosphate sodium salt, 2-mercaptoethanol, 
formaldehyde, and Raltitrexed monohydrate were all purchased from Sigma. 
(6R,S)-5,10-methylenetetrahydrofolate was purchased from Schircks 
Laboratories, Switzerland.  Pemetrexed was purchased from LC Laboratories. 
The fragment library is from Maybridge. 
Steady State and Inhibition Kinetics – The kinetic assay monitored the 
spectral change at 340nm attributed to mTHF being converted to DHF. The 
buffer for the assay contained 12mM formaldehyde, 100mM 2-Mercaptoethanol, 
40mM Tris-Hcl pH 7.4, 20mM MgCl2, 1mM dUMP, 0.75mM EDTA,  0.3mM 
(6R,S)-5,10-methylenetetrahydrofolate, and 400nM purified ThyA. The method 
was first described by Albert Wahba and Friedkin, and refined by Davisson et al. 
The reaction volume was 1.0mL and the absorbance measured in a Cary50 
Spectrophotometer.  A 1.5mM stock solution of mTHF was prepared in reaction 
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buffer, and 0.1M stock solutions of dUMP, FdUMP, Pemetrexed, and Raltitrexed 
were prepared in ultrapure water. All more dilute solutions were made from 
these. For the steady state kinetics, mTHF was held constant at final 
concentrations of 75uM, 150uM, 300uM and 600uM while the concentration of 
dUMP was varied at concentrations of 5uM, 10uM, 20uM, 32uM and 64uM. The 
reaction was initiated by the addition of 1 uL of 150uM thymidylate synthase, 
and the absorbance recorded over a three minute period at room temperature. 
Plots of reaction velocity versus substrate concentration were fit using 
KaleidaGraph, to the Michaelis-Menten equation for a sequential mechanism: 
v=(Vmax[A][B])/([A][B]+Km
A[B]+Km
B[A]+Km
BKs
A]).  
The assay was also used to determine IC50 and Ki values for the inhibitors 
by varying the substrate and corresponding inhibitor concentrations 
(concentrations of dUMP were varied against fixed concentrations of FdUMP, 
and concentrations of mTHF were varied against fixed Pemetrexed or 
Raltitrexed concentrations). The data yielded doubled reciprocal plots that were 
fit to linear regression lines. Plots of reaction rates versus substrate 
concentration were fit using KaleidaGraph to the appropriate Michaelis-Menton 
equation for inhibition by a non-competitive inhibitor, v= (Vmax[B])/ ((1+[I]/Ki)(Km
B 
+[B])), competitive inhibitor, v= (Vmax[B]/(Km
B(1+[I]/Ki+[B])), or mixed inhibitor, v= 
(Vmax[B])/(Ks
A(1+[I]/Ki) + [B](1+[I]/Kis)). 
Differential Scanning Fluorimetry- Inhibitor compounds were screened 
using differential scanning fluoremetry in a 96-well Stratagene RT-PCR system. 
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ThyA enzyme, SYBR Orange, Magnesium Chloride, and HEPES pH 8.0 were 
combined with final concentrations of 6μM, 5X, 5mM, and 330mM, respectively; 
to a final volume of 19μL. 1μL of compound at 100mM was added and the 
solution thoroughly mixed. Controls substituted 1μL of 100mM dUMP or 1μL of 
water, to represent the substrate and apo forms of the enzyme, respectively. 
Temperature range scanned was 25°C to 75°C, with a 0.5°C increase per 
minute. Compounds were selected for further inhibition studies based on 
presenting a melting temperature equal to or greater than that of the dUMP 
bound enzyme. 
2.3 Results 
1. Steady State Kinetics of Mtb Thymidylate Synthase 
 Thymidylate synthase activity was determined using a direct 
spectrophotometric method, in which the oxidation of tetrahydrofolate was 
monitored at 340nm. To probe the order of substrate binding, the purified 
enzyme was assayed with increasing concentrations of either dUMP or mTHF, 
while varying the concentrations of the second substrate. Standard Michaelis-
Menten curves were observed (Figure10). The reciprocal plots were also made 
and fitting of the data allowed the calculation of Km values of 6 µM for dUMP and 
60 µM for mTHF (Table 1). 
 The plots are consistent with an ordered sequential mechanism, with 
dUMP binding the enzyme first. M. tuberculosis ThyA has a very low turnover 
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rate, with an apparent Kcat value of only 4 min
-1. Limited need for TMP because 
of the slow growth of the bacteria may explain this.  
 
 
 
 
 Km (M)   Ki (nM) Ki(M) Ki(M) 
Enzyme dUMP mTHF Kcat (min
-1
) FdUMP Pem Ralt 
M.tb 5 60 4 2 16.8 3.2 
E.coli a 1.2 13 1.9 - 76 5.7 
Human b,c 2.5 12 150 1.7 9.5 0.38 
 
 
 
Table1- Mycobacterium tuberculosis kinetic constants. Mtb values are compared with 
those reported for the E. coli and Human enzymes.  
a
 Values reported by Appleman et al.  
b
  Km and Kcat values reported by Dev et al.  
c
 Ki values reported by Kisliuk et al.  
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Figure 10- Michaelis-Menten Plots. (Left) dUMP is varied at fixed concentrations of mTHF       
(25M, 100M, 300M, 600M), (right) mTHF is varied at fixed concentration of dUMP        
(10M, 32M, 50M, 70M). Error bars are propagation of standard deviations. 
Figure 11- Double reciprocal plots of the data from Figure 10. Shows a sequential 
reaction mechanism. Error bars are propagation of standard deviations.  
  
19 
2. Inhibition of M. tuberculosis ThyA by Pemetrexed, Raltitrexed and      
FdUMP 
 FdUMP, the mechanism- based inhibitor, displayed low nanomolar range 
inhibition, with a Ki = 2nM. This is consistent with what has been reported 
previously (42). The substrate analog contains Fluorine at the 5’ position of the 
pyrimidine ring, where typically hydrogen would be extracted during catalysis. 
The low nanomolar inhibition is the result of a dead-end covalent complex being 
formed between the catalytic cysteine of ThyA and the 5’ C of the pyrimidine.  
 Raltitrexed and Pemetrexed, both chemotherapeutic anti-folates, were 
assayed in their monoglutamated form. Raltitrexed showed the best inhibition 
with a Ki= 3.2M and an IC50 of 3.5M, while Pemetrexed had a Ki= 16.8M and 
an IC50 of 17M. Compared to the human enzyme, Ki = 9.5M for Pemetrexed, 
Mtb shows about 1.7 times weaker binding. For Raltitrexed, Ki=0.38 in huTS, the 
binding in Mtb is about 8.5 times weaker. Both Raltitrexed and Pemetrexed 
show tighter binding in Mtb ThyA versus E. coli, which has Ki values of 5.7M 
and 76M, respectively. 
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Figure 12- Pemetrexed, Raltitrexed, and FdUMP.  
Figure 13 – Thymidylate synthase inhibition. (Top) Michaelis-Menten plots for ThyA inhibition 
by Pemetrexed and Raltitrexed. The concentration of dUMP was held constant at 100M, and 
mTHF was varied at fixed concentrations of inhibitor. (Bottom) Double reciprocal plots, 
indicating noncompetitive inhibition for both drugs. Error bars are propagation of standard 
deviations.  
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Figure 14- Inhibition curves for Pemetrexed and Raltitrexed. (Left) ThyA activity 
measured at increasing concentrations of Pemetrexed. The IC50 occurrs at 17M. 
(Right) ThyA activity measured at increasing concentrations of Raltitrexed. The IC50 
occurs at 3.5M. 
Figure 13 Continued.  
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3. Identification of Lead Compounds by Differential Scanning 
Fluorimetry  
The library of molecules screened consisted of 800 compounds with 
molecular weights of approximately 300 g/mole or less. Aside from the 
compound library, Pemetrexed, Raltitrexed, dUMP, and FdUMP were also 
screened to determine their effect on the melting temperature of apo ThyA, 
which melted at 41.5oC. The natural substrate, dUMP had a Tmelting of 6
oC, 
while Pemetrexed gave a shift of 5oC; this was used as a lower threshold during 
the screening process.   
After eliminating hits due to either non-reproducibility of shift or poor 
solubility, two compounds from the same plate remained; F9 and A7( Figure 15).  
              Of these two hits, F9 had the largest shift compared to the apo enzyme, 
with a Tmelting of approximately 9
oC, while A7 showed a shift of 8oC.   
 
 
                  
 
 
 
Figure 15 – Fragment Structures. (Left) Fragment F9, which displayed a change in melting 
temperature of 9
o
C versus apo ThyA. (Right) Fragment A7, which displayed a change in 
melting temperature of 8
o
C versus apo ThyA. 
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It is not possible to determine which binding site, if either, the fragments 
are bound to. It is also not believed that the degree of shift is necessarily 
correlated with a given level of inhibition; rather, the shift indicates that binding is 
occurring somewhere on the enzyme, and whether it is inhibitory or non-specific 
can only be determined through an X-ray structure. The use of this assay was 
not to identify a strong inhibitor; rather to identify lead compounds that in some 
cases may be linked or modified to form a more potent drug candidate. All 
efforts to crystallize ThyA bound with fragments F9 or A7 have not yet been 
successful, and additional fragment libraries are currently being screened.  
 
 
 
 
 
 
 
 
Figure 16- Thermal shift plot. Plot indicates the melting temperature of apo ThyA 
(blue), ThyA-dUMP (red), ThyA-FragmentF9 (green), and ThyA-Pemetrexed (purple). 
Thermal Shift Profile of ThyA 
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2.4 Discussion 
  
 Inhibition of thymidylate synthase in human cancer cells with antifolates 
such as Pemetrexed and Raltitrexed, as well as with the dUMP analog FdUMP, 
is an avid area of research in recent years. Derivatives of the folate cycle are 
essential for cell growth and replication not only in eukaryotic cells, but in 
prokaryotic cells as well. Inhibition of TS also results in a depletion of the dTTP 
pool and an increase in dUTP.  This results in a decrease in DNA synthesis and 
eventually cell death.   
 With this in mind, Raltitrexed and Pemetrexed were analyzed to 
determine their ability to inhibit M. tuberculosis thymidylate synthase. Each 
inhibited Mtb ThyA in the low micro molar range in vitro, and it is interesting to 
note that Pemetrexed inhibited the Mtb enzyme with a Ki of 16.8M, which is a 
4.5 fold greater affinity than what has previously been reported for E.coli, Ki = 
76M. Given the high degree of structural similarity and conservation of active 
site residues, this large of a difference in Ki was not immediately expected. 
Recent work by Costi et al. has shown the use of dansyl derivatives for the 
inhibition of E.coli and L. casei. N,O-didansyl-L-tyrosine (DDT) showed the 
tightest binding with a Ki of 1.8M in E.coli and 1.4M in L. casei, so was chosen 
to test its inhibition against Mtb ThyA. No inhibition was seen when tested at 
concentrations up to 100M (work not shown).  This result illustrates that small 
ligands have the ability to discriminate between highly conserved enzymes.   
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 The use of differential scanning fluorimetry is an excellent means of 
exploiting such molecules and offers the ability to do so in a quick, easy to 
interpret fashion. Although confirmed hits of novel fragments have yet to be 
established in this study, the method was proven successful in so that a clear 
thermal shift was shown for substrate, dUMP, as well as the known anti folate 
Pemetrexed.  
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3. CRYSTAL STRUCTURES OF BINARY AND TERNARY COMPLEXES OF 
M. tuberculosis THYMIDYLATE SYNTHASE 
3.1 Introduction  
 With the emergence of multidrug-resistant tuberculosis (MDR) and 
extensively drug-resistant TB (XDR), the need for novel therapeutics to combat 
this disease are greater than ever. The last first line drug to hit the market was 
Rifampin, and that was over 40 years ago. Treatment of MDR-TB requires a 24 
month regimen of second line drugs, which is more costly, toxic, and less 
effective than first-line drugs. Even with over site by the World Health 
Organization to ensure proper use of second line TB drugs, it has still been 
reported that MDR TB strains have become resistant to these. The outcome of 
not developing a new first line anti-tubercular drug soon could be the outbreak of 
a very deadly, drug resistant strain of TB.  
 Thymidylate synthase has been much studied as its role as a 
chemotherapeutic agent, as well as its potential as an anti-microbial. Crystal 
structures of ThyA from E. coli, Cryptococcus neoformans, Lactobacillus casei, 
and human have all been solved and show high levels of conservation in the 
overall fold of the enzyme, as well as in catalytic residues. Variations in Ki of 
known inhibitors, though, lead to the conclusion that bacterial or species specific 
thymidylate synthase drugs are possible. A thorough understanding of the 
structure of Mycobacterium tuberculosis thymidylate synthase opens the door to 
being able to design such a drug.  
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Furthermore, mycobacterium lacks the gene encoding Thymidine Kinase, 
which in most organisms catalyzes the conversion of thymidine to dTMP via a 
phosphate transfer from ATP.  This underscores the significance and essentiality 
of de novo TMP synthesis in this organism. 
3.2 Experimental Procedures 
 Chemicals- 2′-Deoxyuridine 5′-monophosphate disodium salt, 5-Fluoro-
2′-deoxyuridine 5′-monophosphate sodium salt, and Raltitrexed monohydrate 
were all purchased from Sigma. Pemetrexed was purchased from LC 
Laboratories. 
 Cloning, Expression and Purification – The ThyA gene, Rv2764c from 
M. tuberculosis H37Rv genome, was identified from TubercuList sequence data 
base. The ThyA gene was amplified using M. tuberculosis genomic DNA as a 
template and cloned into a pET28b expression vector (Novagen) with an N-
terminal His tag. The vector was transformed into Escherichia coli 
overexpression strain, BL21(DE3). Cells were grown at 37oC until they reached 
an optical density of 0.6, and then induced with 1mM isopropyl-1-thio-β-D-
galactopyranoside. The temperature was then reduced to 18 oC for 24 hours. 
The cells were spun and pellets re-suspended in 20mM Tris-HCl pH 7.0 
containing 100mM NaCl and 10mM imidazole. The cell extract was applied to a 
5-mL nickel-nitrilotriacetic acid column (GE Lifesciences), and the target protein 
was eluted using an imidazole gradient. ThyA eluted at approximately 100mM 
imidazole. The eluted protein was dialyzed overnight against 4 liters of 20mM 
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Tris-HCl pH 7.0, containing 100mM NaCl, 10% glycerol, and 1mM DTT. The 
protein was then concentrated with Amicon 10K concentrating tubes to a final 
concentration of 15mg/mL. The final protein was greater than 95% pure as seen 
on an SDS-PAGE gel.   
Crystallization – The initial crystallization condition was obtained using 
Wizard II from Emerald BioSystems. Crystals were grown using the hanging 
drop vapor diffusion method at 16oC. Crystals of the binary complexes, ThyA-
dUMP and ThyA-FdUMP, were obtained by incubating 15mg/mL of purified thyA 
with 3mM of the respective compound along with 1mM spermidine 
tetrahydrochloride for a period of two hours. Crystals of the ternary complex, 
ThyA-dUMP-Pemetrexed, were obtained by incubating with 3mM of dUMP, 3mM 
Pemetrexed, and 1mM spermidine tetrahydrochloride for 2 hours. In both cases, 
3 uL of incubated 15 mg/mL protein was added to 2uL of reservoir buffer 
containing 0.1M Tris pH 7.0, 0.2M NaCl, and 30% (w/v) PEG-3000.  Crystals 
appeared within 24-48 hours. 
Data Collection and Processing- High resolution data was collected at 
beamlines 19id and 23id at the Advanced Photon Source, Argonne National 
Laboratory. All data was indexed and scaled using HKL2006. Unit cell 
dimensions for dUMP bound crystals were a = 184.9, b = 84.9, c = 130.1 α = 
90.0, β = 107.9, γ = 90.0; for fdUMP crystals they were a = 184.3, b = 82.3, c = 
125.9 α = 90.0, β = 131.0, γ = 90.0; for Pemetrexed- dUMP bound crystals they 
were a = 100.1, b = 57.0, c = 113.7 α = 90.0, β = 107.9, γ = 90.0. All crystals 
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were space group C2; however, the Pemetrexed-dUMP ternary complex 
consisted of 2 molecules in the asymmetric unit, while dUMP and FdUMP binary 
complexes each displayed 4 molecules in the asymmetric unit.  
Structure Determination of Substrate Bound Thymidylate Synthase - 
The dUMP bound structure of Mtb thymidylate synthase was solved by 
molecular replacement using MolRep of the CCP4 suite of programs. Molecular 
replacement uses the phases from structure factors of a known protein as initial 
estimates of phases for a new protein. The known protein is the phasing model, 
which in this case was from Escherichia coli Thymidylate synthase (PDB 2FTQ). 
This method calculates initial phases by placing a model of the known protein 
(E.coli ThyA), in the asymmetric unit of the new protein (Mtb ThyA). The search 
is broken up into two parts: rotational and translational. In the rotational search, 
the orientation of the molecules is determined by the match of intramolecular 
Patterson vectors. The intramolecular Patterson vectors are used (distances 
between ~10-4Å) because they are indicative of the relative locations of 
secondary structure elements, whereas very large distances will contain 
intermolecular vectors, which differ for each packing situation and may not be 
useful.  Correlation coefficients were calculated for each rotation of the 
Patterson map over all angles. The orientation giving the highest correlation 
coefficient was chosen as the best orientation for the phasing model.  
Next, in the translation search, the criterion is the correspondence 
between the expected structure-factor amplitudes from the model in a given trial 
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location and the actual amplitudes derived from the native data on the desired 
protein. The R-factor is monitored which compares the overall agreement 
between the amplitudes of two sets of structure factors. A small R-factor 
indicates that the observed and calculated intensities agree with each other.  A 
solution was found and refinement was done by rigid body and restrained 
refinement, using RefMac5, followed by simulated annealing using Phenix 
refine, and another round of restrained refinement. The substrate dUMP was 
made using PRODRG and fit to the electron density map using Coot. Several 
rounds of manual refinement were performed. The model was subjected to 
another round of refinement in RefMac and solvent molecules were added 
before a final round of refinement was performed. The Rwork and Rfree values 
were 0.16 and 0.21, respectively. 
Structure Determination of Inhibitor Bound Thymidylate Synthase- 
Inhibitor bound Mtb thymidylate synthase crystals, containing either bound 
FdUMP in a binary complex or dUMP-Pemetrexed in a ternary complex, were 
solved by molecular replacement with the solved Mtb thymidylate synthase-UMP 
bound structure as a search model. Water molecules and dUMP were removed 
from the structure prior to molecular replacement.  Refinement was carried out 
using RefMac5 and ligands fit to the electron density in Coot. After final 
refinement, the R factors for the FdUMP structure were 0.21 and 0.26 and the R 
factors for the dUMP-Pemetrexed structure were 0.15 and 0.19.  
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3.3 Results 
1.  Crystal Structures of M. tuberculosis ThyA Binary Complexes,  
      ThyA-dUMP and ThyA-FdUMP 
The x-ray structure of the recombinant Mtb ThyA-dUMP binary complex 
was solved from electron density maps calculated by molecular replacement 
with Escherichia coli Thymidylate synthase.  The crystals grew after incubation 
of the protein with dUMP, and the space group of the crystals was found to be 
C2. The structure has been refined to an Rwork of 0.16 and an Rfree of 0.21. The 
monomeric subunit of Mtb thymidylate synthase has 83% identity with the 
previously solved structure from E. coli. The monomeric unit folds into three 
domains consisting of a large six-stranded mixed -sheet surrounded by -
helices (Figure 17). A total of 23% of the enzyme is comprised of -sheets, 
including the dimer interface which is a -sandwich.  The asymmetric unit was 
comprised of two dimers, being stabilized at the dimer interface with a spermine 
molecule, which was used as an additive during crystallization.  
The FdUMP binary complex was solved from electron density maps 
calculated by molecular replacement with the Mtb ThyA-dUMP structure, with 
calculated Rwork and Rfree values of 0.21 and 0.26 respectively. The asymmetric 
unit was comprised of a single biological dimer. The overall structure of the 
ThyA-FdUMP complex is identical with that of the dUMP bound enzyme, with 
one exception. In the FdUMP structure, the fluorine atom makes hydrogen 
bonding interactions with a conserved water molecule as well as with the OH 
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group of Tyr94 (Figure 18).  In both structures, the nucleotide binds to the open 
conformation of the enzyme, in position to make a covalent adduct between C-6 
of the pyrimidine ring, and Cys146 upon binding of cofactor.  
 
 
 
Figure 17- ThyA Domains and ThyA-dUMP/ThyA-FdUMP Superposition. (Top) Monomer 
of Mycobacterium TS with Helices and -strands indicated. (Bottom) Superposition of 
ThyA-dUMP and ThyA-FdUMP complexes 
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Figure 18- FdUMP Electron Density (Active Site). Electron density map showing the 
interaction of the 5’fluoro group with bridging Hydrogen bonds between Tyr94 and 
an active site water molecule. This interaction can’t be made in the dUMP bound 
enzyme. 
Figure 19- dUMP/FdUMP superposition of active site binding. Arg126 and 
Arg127 are from the opposing monomer.  Five interactions stabilize the 
5’Phosphate. 
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 Pemetrexed dUMP FdUMP 
    
Resolution 22.3-1.7 32.0-2.5 42.9-2.4 
 
# Reflections    
      Working Set 52863 49396 50786 
      Test Set 2775 2659 2712 
 
Rcrys 0.15 0.16 0.21 
Rfree 0.19 0.21 0.26 
    
Average B 21.4 Å2 46 Å2 44 Å2 
Rms from ideal    
       Bond Length(Å) 0.005 0.007 0.008 
       Bond Angle (o) 0.74 1.13 1.15 
    
 
 It has been shown by Lew et al., that in the absence of mTHF, FdUMP is 
at equilibrium with its covalent and non-covalent form. The presence of a folate 
shifts this equilibrium towards covalent adduct formation. This is consistent with 
Table2- Data Collection and Refinement Statistics 
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the binary structure of Mtb ThyA-FdUMP, in that no covalent adduct in observed.  
Stability of both dUMP and FdUMP is provided through several conserved 
hydrogen bonding interactions: the 2-oxo group of the pyrimidine with the 
backbone amide of Asp169, the N-3 of the pyrimidine and the Fluorine with 
Asn177, the 3’Hydroxyl with His207 and Tyr209, and the 5’Phosphate makes 
five interactions with Arg21, Arg126-127 of the opposing monomer, Arg166, and 
Ser167 (Figure 19). The five hydrogen bonding interactions with the phosphate 
tail of dUMP may account for the fact that 2’-deoxyuridine is not a substrate for 
ThyA (Reyes&Heidelberger, 1965). Hydrophobic contacts made by the 
pyrimidine include side-chains of residues Trp80, Tyr94, Leu143, Cys146, 
His147, Gln165, Ser167, and main chains of residues Ser167, Cys168, and 
Gly173. The ribose of dUMP/FdUMP makes hydrophobic interactions with the 
side chains of Leu143, Tyr209, Arg126, and the main chain and side chain of 
Asp169. Data collection and refinement statistic for all structures can be seen in 
Table 2.  
2. Ternary Structure of Mtb ThyA-dUMP-Pemetrexed 
The x-ray structure of the recombinant ternary complex, Mtb ThyA-dUMP-
Pemetrexed, was solved from electron density maps calculated by molecular 
replacement with the solved Mtb TS-dUMP structure. The final model has Rwork 
and Rfree values of 0.15 and 0.19, respectively, and a space group of C2 with a 
full physiological dimer in the asymmetric unit (Figure 20).  
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Pemetrexed was found to be bound in the active site of each monomer, 
with the fused ring system of Pemetrexed centered over the dUMP pyrimidine, 
causing planar ring stacking interactions which orient the inhibitor (Figure 21). 
No covalent bond was found between the C6 of dUMP and Cys146 after 
refinement, with a separation of 2.51Å. This is in contrast to what is seen in the 
EcTS crystal structure with the polyglutamated Pemetrexed, where a covalent 
adduct is seen to form in both binding pockets. Polyglutamation may lead to an 
Figure 20- ThyA dimer with bound dUMP and Pemetrexed. 
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alternate conformation of Pemetrexed, which forces dUMP into the non-
productive covalent complex. 
   
 
 
 
 
 
 The interactions made by the ring system of Pemetrexed parallel those 
made by the human thymidylate synthase, with two key differences. In human 
TS, Met311 is involved in a hydrophobic interaction with the ring system, which 
cannot occur in Mtb ThyA because this residue is a Valine. Also, human ThyA 
has an Asn which acts as a hydrogen bond acceptor from the N7 of the pyrrolo 
Figure 21- ThyA active site with bound dUMP/Pemetrexed. The fused ring system 
of Pemetrexed centers over the dUMP pyrimidine, causing planar ring stacking 
interactions which orient the inhibitor 
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ring of Pemetrexed; this residue in Mtb ThyA is a Trp.  Pemetrexed is located in 
the folate binding site cushioned by five main hydrophobic interactions; Ile79, 
Trp80, Trp83, Leu172, and Phe176 (Figure 23).  Pemetrexed includes an 
exocyclic amino group at the 2-position of the pyrrolo ring, which forms a 
hydrogen bond interaction with the backbone carbonyl of Ala262. There is also a 
conserved water molecule that mediates hydrogen bonding between the same 
amino group of Pemetrexed, the δ2-O of Asp169, and the protein backbone at 
Ala262. 
 
 
 
 
  
Figure 22- Superposition of ThyA-dUMP binary complex (gold) with ThyA-dUMP-Pemetrexed 
ternary complex (cyan). Shows closure of the active site upon binding of Pemetrexed (arrow).  
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3.4 Discussion 
 M. tuberculosis thymidylate synthase is an obligate homodimer, and 
contains one active site per subunit. Each active site consists of catalytic 
residues from each monomer, meaning that a single subunit on its own would 
not be active. The binding pocket and catalytic residues are highly conserved 
across species. The residues involved in ligand binding and catalysis for Mtb 
ThyA have been identified as follows: Arg166 for dUMP binding, Asp169 for 
mTHF or anti-folate binding, Cys146 as the nucleophile attacking C6 of the 
pyrimidine, Tyr-94 for proton abstraction at the C5 position of dUMP, and Glu58 
is believed to be involved in cofactor elimination from the covalent ternary 
complex.  
Figure 23- Pemetrexed hydrophobic interactions. Pemetrexed is located in the 
folate binding site cushioned by five main hydrophobic interactions; Ile79, Trp80, 
Trp83, Leu172, and Phe176 
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This study reports the first crystal structures of Mycobacterium 
tuberculosis thymidylate synthase, which provides valuable structural insight into 
the binding of substrate and inhibitors to Mtb. It also allowed for the comparison 
of Mtb ThyA and other thymidylate synthases. In ternary complex with 
Pemetrexed and dUMP, Mtb ThyA fails to form a covalent adduct with the 
substrate, and the Ki  of 16.8M  is almost 2-fold weaker than that of huTS, Ki = 
9.5M, where a covalent bond is evident in the crystal structure. Coupled with 
the inability to form a hydrogen bond at the N7 position of the Pemetrexed 
pyrrolo ring, this may explain the weakened affinity of the mycobacterium TS.  In 
both Mtb and human structures, binding of Pemetrexed causes an ordering of 
the C-terminus of the enzyme, resulting in a closure of the active site cavity 
(Figure 21). In the case of substrate and cofactor, this would block the active site 
from solvent molecules and allow for catalysis to proceed. Aside from the active 
site, M. tuberculosis TS differs from the human TS by the conversion of a 
cysteine in the human enzyme to a serine in the mycobacterium. This residue is 
located on the beta sheet that forms the dimer interface. In the human enzyme, 
the cysteine allows thymidylate synthase to bind its mRNA and regulate its own 
translation. This suggests that Mtb ThyA expression levels may be dominated by 
regulation of RNA transcription, rather than autologous translational feedback 
loops.  
Despite the fact that the crystal structure of the ternary complex ThyA-
dUMP-Raltitrexed has not been fully solved (still in refinement), the kinetics 
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indicate that in vitro, Raltitrexed has a Ki of 3.2M, which makes it about a 5 fold 
better inhibitor than Pemetrexed; both in their mono-glutamated form. This may 
even increase substantially in vivo upon polyglutamation, and whole cell assays 
should be performed on each.  
This lab is continuing to work on solving crystal structures of Mtb ThyA in 
complex with known anti-folates, as well as lead compounds identified through 
fluorescence-based thermal shift assays. Solving of the apo structure is also of 
interest because it would help in understanding the overall mechanics of active 
site closure and what rearrangements take place upon dUMP binding.  
Furthermore, product bound crystals are of interest to understand what changes 
regulate release of DHF and dTMP after catalysis. Currently, crystals of ThyA-
dTMP-Pemetrexed have been grown, and work is being done to crystalize the 
ternary complex ThyA-FdUMP-DHF. Together, these may give the insight 
necessary to answer these questions.   
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4. SUMMARY 
 
Tuberculosis is currently treated with a plethora of first and second line 
antibiotics. Two of these drugs, Isoniazid and Ethambutol, target different areas 
of the bacterial cell wall. Isoniazid is the synthesis of mycolic acid, while 
Ethambutol inhibits arabinogalactan synthesis. The most recently introduced 
drug, Rifampicin, inhibits the beta-subunit of the RNA polymerase of 
prokaryotes. Despite therapeutic regimens containing combinations of these 
drugs, multi-drug resistant and extensively drug resistant strains of 
Mycobacterium tuberculosis, the causative agent of TB, continue to arise.  
Thymidylate synthase has proven to be an important target in the 
treatment of many types of cancer including non-small cell lung, breast, 
colorectal, head and neck, gastric, bladder, cervix, and pancreas cancers. ThyA 
plays a crucial role in cell proliferation via production of TMP, and also through 
its role in the folate cycle (Figure 24). Folate deficiency inhibits cellular 
proliferation, disturbs cell cycling, causes genetic damage, and eventually 
results in cell death (43-45). 
 Raltitrexed and Pemetrexed are both antifolates that enter cancer cells 
via the reduced folate carrier as well as the -folate receptor, which is 
overexpressed in some epithelial tumors (46).  Once in the cell, Raltitrexed and 
Pemetrexed become polyglutamated by folylpolyglutamyl synthase, which 
increases the size and ionization state of the molecule. This decreases cellular 
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efflux, which leaves the drugs trapped in the cell for longer periods of time to act 
on their target, ThyA.  
 
 
 
 
 
 
Thymidylate synthase is an essential enzyme in the survival of 
Mycobacterium tuberculosis, therefore it’s potential as a drug target in fighting 
this disease as well, has been explored. Pemetrexed and Raltitrexed in their 
monoglutamated forms have been shown in this study to have in vitro activity in 
the low micro molar range. This leads to the hypothesis that in vivo activity will 
be much greater, assuming transport into the cell and polyglutamation.  
Figure 24- Folate cycle. Folate deficiency inhibits cellular proliferation, disturbs cell 
cycling, causes genetic damage, and eventually results in cell death. 
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Given that mycobacterium lacks Thymidine Kinase, it may prove that 
antifolate inhibition of ThyA does not have to be species specific in fighting 
tuberculosis. Given the rate of success in treating colorectal cancer with 
Raltitrexed, and pancreas, bladder, and cervical cancer with Pemetrexed, similar 
results might be observed if Raltitrexed or Pemetrexed are used to treat Mtb. 
 In vivo experiments to determine the toxicity of these two drugs on 
Mycobacterium tuberculosis would define the extent to which polyglutamation 
increases their effectiveness, as well as determine whether there is transport of 
the drug into the bacterial cell. The design of a lipophilic anti-folate may be 
necessary, but utilizing the crystal structure of bound Pemetrexed as a scaffold, 
the design of a novel antifolate to fight Mtb is possible.  
The crystal structures presented here open the door to the specific design 
of Mycobacterial antibiotics. However, considering the homology with human 
thymidylate synthase, it is prominent that the design of anti folates of a dual 
nature (anti-cancer/anti-bacterial) is also possible.  
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